WHAT IS CLAIMED IS:

1. An amorphous solid dispersion comprising a linear poly(acrylic acid) and an active pharmaceutical ingredient, the linear poly(acrylic acid) having a Brookfield viscosity at 25°C of at least 100 cP.

2. The amorphous solid dispersion of claim 1, wherein a ratio by weight of active pharmaceutical ingredient: poly(acrylic acid) in the amorphous solid dispersion is at least 1:10, or at least 1:6, or at least 1:3, or at least 1:1.5, or at least 1:1, or at least 2:1, or at least 3:1, or at least 4:1, or up to 6:1, or up to 5:1, or up to 4.5:1.

3. The amorphous solid dispersion of claim 1 or 2, wherein the Brookfield viscosity at 25°C of the linear poly(acrylic acid) is at least 200 cP, or at least 250 cP, or at least 300 cP, or at least 400 cP.

4. The amorphous solid dispersion of any one of claims 1-3, wherein the linear poly(acrylic acid) has a Brookfield viscosity at 25°C of no more 3000 cP, or no more than 2,500 cP, or no more than 2200 cP, or no more than 2100 cP.

5. The amorphous solid dispersion of any one of claims 1-4, wherein the amorphous solid dispersion comprises at least 10 wt.% linear poly(acrylic acid), or at least 15 wt.% linear poly(acrylic acid), or at least 20 wt.% linear poly(acrylic acid), or at least 25 wt.% linear poly(acrylic acid).

6. The amorphous solid dispersion of any one of claims 1-5, wherein the amorphous solid dispersion comprises no more than 95 wt.% linear poly(acrylic acid), or no more than 80 wt.% linear poly(acrylic acid), or no more than 60 wt.% linear poly(acrylic acid), or no more than 50 wt.% linear poly(acrylic acid), or no more than 40 wt.% linear poly(acrylic acid), or no more than 30 wt.% linear poly(acrylic acid).

7. The amorphous solid dispersion of any one of claims 1-6, wherein the linear poly(acrylic acid) and the active pharmaceutical ingredient together comprise at least 80 wt.%, or at least 90 wt.%, or at least 95 wt.% of the amorphous solid dispersion.

8. The amorphous solid dispersion of any one of claims 1-7, wherein the amorphous solid dispersion comprises no more than 10 wt. % water, or no more than 5 wt. % water, or no more than 1 wt. % water, or no water.

9. The amorphous solid dispersion of any one of claims 1-8, wherein the active pharmaceutical ingredient is in BCS class II or BCS class IV.

10. A product comprising the amorphous solid dispersion of any one of claims 1-9.

11. The product of claim 10, further comprising at least one excipient or adjuvant.

12. The product of claim 10 or 11, wherein the product is in a form selected from the group consisting of granules, capsules, pellets, tablets, films, and implants.

13. A method of administering an active pharmaceutical ingredient to a person or non-human animal in need of treatment comprising orally administering an amorphous solid dispersion of any one of claims 1-9 or the product of any one of claims 10-12 to the person or animal.

14. A method of forming an amorphous solid dispersion of an active pharmaceutical ingredient, the method comprising:

forming a liquid dispersion comprising a linear poly(acrylic acid), an active pharmaceutical ingredient, and a solvent system, the linear poly(acrylic acid) having a Brookfield viscosity at 25°C of at least 100 cP; and

evaporating the solvent system from the liquid dispersion to form an amorphous solid dispersion.

15. The method of claim 14, wherein a weight ratio of active pharmaceutical ingredient: linear poly(acrylic acid) in the liquid dispersion is at least 15:85, or at least 30:70, or at least 40:60, or at least 50:50, or at least 70:30.

16. The method of claim 14 or 15, wherein a weight ratio of active pharmaceutical ingredient: linear poly(acrylic acid) in the liquid dispersion is no more than 90:10, or no more than 85:15.

17. The method of any one of claims 14-16, wherein the linear poly(acrylic acid) has a Brookfield viscosity at 25°C, of at least 200 cP, or at least 250 cP, or at least 300 cP, or at least 400 cP.

18. The method of any one of claims 14-17, wherein the linear poly(acrylic acid) has a Brookfield viscosity of no more 3000 cP, or no more than 2,500 cP, or no more than 2200 cP, or no more than 2100 cP.

19. The method of any one of claims 14-18, wherein the linear poly(acrylic acid) is one which has been formed in a solvent system which is substantially free of water.

20. The method of any one of claims 14-19, wherein the linear poly(acrylic acid) is one which has been formed in a solvent system selected from a) ethyl acetate and b) a mixture of ethyl acetate and cyclohexane.

21. The method of any one of claims 14-20, wherein the amorphous solid dispersion comprises at least 10 wt.% linear poly(acrylic acid), or at least 15 wt.% linear poly(acrylic acid), or at least 20 wt.% linear poly(acrylic acid), or at least 25 wt.% linear poly(acrylic acid).

22. The method of any one of claims 14-21, wherein the amorphous solid dispersion comprises no more than 95 wt.% linear poly(acrylic acid), or no more than 80 wt.% linear poly(acrylic acid), or no more than 60 wt.% linear poly(acrylic acid), or no more than 50 wt.% linear poly(acrylic acid), or no more than 40 wt.% linear poly(acrylic acid), or no more than 30 wt.% linear poly(acrylic acid).

23. The method of any one of claims 14-22, wherein the linear poly(acrylic acid) and the active agent together comprise at least 80 wt.%, or at least 90 wt.%, or at least 95 wt.% of the amorphous solid dispersion.

24. The method of any one of claims 14-22, wherein the amorphous solid dispersion comprises no more than 10 wt. % water, or no more than 5 wt. % water, or no more than 1 wt. % water, or no water.

25. The method of any one of claims 14-24, wherein the forming of the dispersion of the linear poly(acrylic acid) and the active pharmaceutical ingredient comprises dissolving the linear poly(acrylic acid), in powder form in the solvent system or in at least one of a plurality of solvents used in the solvent system.

26. The method of any one of claims 14-25, wherein the solvent system comprises at least one of an organic polar protic solvent and a polar aprotic solvent.

27. The method of claim 26, wherein the solvent system comprises at least one organic polar protic solvent selected from C_1-C_6 alcohols, and mixtures thereof.

28. The method of claim 26 or claim 27, wherein the solvent system comprises at least one polar aprotic solvent selected from dichloromethane, C_3-C_8 ketones, C_3-C_8 ethers, and mixtures thereof.

29. The method of any one of claims 14-28 wherein the active pharmaceutical ingredient is in BCS class II or BCS class IV.

30. The method of any one of claims 14-29, wherein the evaporating of the solvent system from the liquid dispersion comprises spray drying.

31. The method of any one of claims 14-30, further comprising preparing a product comprising the amorphous solid dispersion, the product being selected from granules, capsules, pellets, tablets, films, and implants.

32. An amorphous solid dispersion formed by the method of any one of claims 14-31.

33. A product comprising the amorphous solid dispersion of claim 32 and at least one excipient or adjuvant.

34. The product of claim 33, wherein the product is in a form selected from the group consisting of granules, capsules, pellets, tablets, films, and implants.

35. A method of administering an active pharmaceutical ingredient to a person or animal in need of treatment comprising orally administering an amorphous solid dispersion formed by the method of any one of claims 14-30 or product formed by the method of claim 31 to the person or animal.